Therapeutic effect of vitamin D3 in multiple sclerosis patients

Immunological Investigations

Volumn 40, Issue 6, 2011, Pages 627-639

  Mosayebi, Ghasem ^a,c   Ghazavi, Ali ^a   Ghasami, Keyvan ^a   Jand, Yahya ^a   Kokhaei, Parviz ^b  

^a ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ARAK UNIVERSITY   (Iran)

Author keywords

Cell Proliferation; Cytokines; Multiple Sclerosis; Vitamin D3

Indexed keywords

25 HYDROXYVITAMIN D; BETA1A INTERFERON; CINNOVEX; COLECALCIFEROL; GADOLINIUM; INTERLEUKIN 10; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; CALCITRIOL; CELL PROLIFERATION; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHYTOHEMAGGLUTININS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959601472     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2011.573041     Document Type: Article

References (46)

1. Ascherio, A., Munger, K. (2008). Epidemiology of multiple sclerosis: From risk factors to prevention. Semin. Neurol. 28:17-28. (Pubitemid 351273081)
2. Becklund, B. R., Severson, K. S., Vang, S. V., Deluca, H. F. (2010). UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc. Natl. Acad. Sci. USA 107:6418-6423.
3. Bouillon, R., Eelen, G., Verlinden, L., Mathieu, C., Carmeliet, G., Verstuyf, A. (2006). Vitamin D and cancer. J. Steroid Biochem. Mol. Biol. 102:156-162. (Pubitemid 44781185)
4. Branisteanu, D. D., Waer, M., Sobis, H., Marcelis, S., Vandeputte, M., Bouillon, R. (1995). Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J. Neuroimmunol. 61:151-160.
5. Brosnan, C. F., Raine, C. S. (1996). Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 6:243-257. (Pubitemid 26246381)
6. Cantorna, M. T., Hayes,C. E., DeLuca, H. F. (1996). 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 93:7861-7864. (Pubitemid 26277129)
7. Cantorna, M. T., Woodward, W. D., Hayes, C. E., DeLuca, H. F. (1998). 1,25- dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 160:5314-5319. (Pubitemid 28267819)
8. Correale, J., Gilmore, W., McMillan, M., Li, S., McCarthy, K., Le, T., Weiner, L. P. (1995). Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154:2959-2968.
9. Dhib-Jalbut, S. (2007). Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 68, S13-21; discussion S43-54. (Pubitemid 46848607)
10. Goldberg, P., Fleming, M. C., Picard, E. H. (1986). Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med. Hypotheses 21:193-200. (Pubitemid 17201931)
11. Imitola, J., Chitnis, T., Khoury, S. J. (2005). Cytokines in multiple sclerosis: From bench to bedside. Pharmaco.l Ther. 106:163-177. (Pubitemid 40603863)
12. Johns, L. D., Flanders, K. C., Ranges, G. E., Sriram, S. (1991). Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol. 147:1792-1796.
13. Kimball, S. M., Ursell, M. R., OConnor, P., Vieth, R. (2007). Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 86:645-651. (Pubitemid 47435831)
14. Korn, T. (2008). Pathophysiology of multiple sclerosis. J. Neurol. 255 Suppl 6:2-6.
15. Lemire, J. M., Adams, J. S., Kermani-Arab, V., Bakke, A. C., Sakai, R., Jordan, S. C. (1985). 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J. Immunol. 34:3032-3035. (Pubitemid 15249817)
16. Lemire, J. M., Archer, D. C. (1991). 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87:1103-1107.
17. Mahon, B. D., Gordon, S. A., Cruz, J., Cosman, F., Cantorna, M. T. (2003). Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 134:128-132. (Pubitemid 36050838)
18. Matheu, V., Back, O., Mondoc, E., Issazadeh-Navikas, S. (2003). Dual effects of vitamin D-induced alteration of TH1/TH2 cytokine expression: Enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. J Allergy Clin. Immunol. 112:585-592. (Pubitemid 37108564)
19. McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Weinshenker, B. Y., Wolinsky, J. S. (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50: 121-127.
20. Mokhtarian, F., Shi, Y., Shirazian, D., Morgante, L., Miller, A., Grob, D. (1994). Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. J. Immunol. 152:6003-6010. (Pubitemid 24174183)
21. Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., Ascherio, A. (2006). Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832-2838. (Pubitemid 44969183)
22. Munger, K. L., Zhang, S. M., OReilly, E., Hernan, M. A., Olek, M. J., Willett, W. C., Ascherio, A. (2004). Vitamin D intake and incidence ofmultiple sclerosis. Neurology 62:60-65. (Pubitemid 38082871)
23. Muthian, G., Raikwar, H. P., Rajasingh, J., Bright, J. J. (2006). 1,25 Dihydroxyvitamin- D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res. 83: 1299-1309. (Pubitemid 43668013)
24. Myhr, K. M. (2009). Vitamin D treatment in multiple sclerosis. J. Neurol. Sci. 286: 104-108.
25. Nashold, F. E., Hoag, K. A., Goverman, J., Hayes, C. E. (2001). Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119, 16-29. (Pubitemid 32781724)
26. Nashold, F. E., Miller, D. J., Hayes, C. E. (2000). 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 103:171-179. (Pubitemid 30079729)
27. Nieves, J., Cosman, F., Herbert, J., Shen, V., Lindsay, R. (1994). High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687-1692. (Pubitemid 24286648)
28. Nordvik, I., Myhr, K.M., Nyland, H., Bjerve, K.S. (2000). Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol. Scand. 102: 143-149. (Pubitemid 30645133)
29. Ozgocmen, S., Bulut, S., Ilhan, N., Gulkesen, A., Ardicoglu, O., Ozkan, Y. (2005). Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J. Bone Miner. Metab. 23:309-313. (Pubitemid 40875090)
30. Pelfrey, C. M., Rudick, R. A., Cotleur, A. C., Lee, J. C., Tary-Lehmann, M., Lehmann, P. V. (2000). Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 165:1641-1651. (Pubitemid 30604603)
31. Pierrot-Deseilligny, C. (2009). Clinical implications of a possible role of vitamin D in multiple sclerosis. J. Neurol. 256:1468-1479.
32. Provvedini, D. M., Tsoukas, C. D., Deftos, L. J., Manolagas, S. C. (1983). 1,25- dihydroxyvitamin D3 receptors in human leukocytes. Science 221:1181-1183. (Pubitemid 13001231)
33. Raine, C. S., Wu, E J., Ivanyi, J., Katz, D., Brosnan, C. F. (1996). Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab. Invest. 75:109-123. (Pubitemid 26255238)
34. Simon, K.C., Munger, K.L., Xing, Y., Ascherio, A. (2010). Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult. Scler. 16:133-138.
35. Smolders, J., Damoiseaux, J., Menheere, P., Hupperts, R. (2008a). Vitamin D as an immune modulator in multiple sclerosis: A review. J. Neuroimmunol. 194:7-17.
36. Smolders, J., Menheere, P., Kessels, A., Damoiseaux, J., Hupperts, R. (2008b). Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 14:1220-1224.
37. Smolders, J., Menheere, P., Thewissen, M., Peelen, E., Tervaert, J. W., Hupperts, R., Damoiseaux, J. (2010). Regulatory T cell function correlates with serum 25- hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J. Ster. Biochem.Mol. Biol.121:243-246.
38. Soilu-Hãnninen, M., Airas, L., Mononen, I., Heikkilã, A., Viljanen, M., Hãnninen, A. (2005). 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11:266-271. (Pubitemid 40775180)
39. Thorbecke, G. J., Umetsu, D. T., deKruyff, R. H., Hansen, G., Chen, L. Z., Hochwald, G. M. (2000). When engineered to produce latent TGF-beta1, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev. 11:89-96. (Pubitemid 30169729)
40. van der Mei, I. A., Ponsonby, A. L., Blizzard, L., Dwyer, T. (2001). Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20:168-174. (Pubitemid 32718873)
41. van der Mei, I. A., Ponsonby, A. L., Engelsen, O., Pasco, J. A., McGrath, J. J., Eyles, D. W., Blizzard, L., Dwyer, T., Lucas, R., Jones, G. (2007). The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ. Health Perspect. 115:1132-1139. (Pubitemid 351802343)
42. Van Etten, E., Branisteanu, D. D., Overbergh, L., Bouillon, R., Verstuyf, A., Mathieu, C. (2003). Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 32:397-404. (Pubitemid 36407540)
43. Veldman, C. M., Cantorna, M. T., DeLuca, H. F. (2000). Expression of 1,25- dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 37:334-338. (Pubitemid 30120270)
44. Wingerchuk, D. M., Lesaux, J., Rice, G. P., Kremenchutzky, M., Ebers, G. C. (2005). A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psych. 76:1294-1296. (Pubitemid 41208389)
45. Winquist, R. J., Kwong, A., Ramachandran, R., Jain, J. (2007). The complex etiology of multiple sclerosis. Biochem. Pharmacol. 74:1321-1329. (Pubitemid 47449688)
46. Zuvich, R. L., McCauley, J. L., Pericak-Vance, M. A., Haines, J. L. (2009). Genetics and pathogenesis of multiple sclerosis. Semin. Immunol. 21:328-333.